Skip to main content

Table 1 Proteolytic enzymes, CEA and CA 19-9 in patients with colorectal cancer, ulcerative colitis, adenoma and controls.

From: Tumor marker utility and prognostic relevance of cathepsin B, cathepsin L, urokinase-type plasminogen activator, plasminogen activator inhibitor type-1, CEA and CA 19-9 in colorectal cancer

  CATB CATL uPA PAI-1 CEA CA 19-9
Colorectal cancer (n = 56) 8.75*§
(2.4–39.3)
1.10*§
(1.0–35.3)
0.29*§
(0.1–0.79)
52.45*§
(13.5–138.6)
2.40
(0.4–235.0)
9.15
(1.0–540.0)
Ulcerative colitis
(n = 25)
4.37
(2.8–7.2)
1.10
(1.0–1.7)
0.20
(0.18–0.23)
12.60
(8.8–17.6)
3.15
(0.8–11.5)
9.00
(4.5–32.0)
Colorectal adenoma (n = 26) 4.45#
(4.2–10.3)
1.25#
(1.0–6.5)
0.20
(0.16–0.53)
14.05#
(10.5–65.5)
3.55
(0.7–5.7)
10.27
(3.7–41.0)
Controls
(n = 35)
3.80
(1.4–5.8)
1.00
(1.0–2.1)
0.19
(0.16–0.27)
10.70
(1.87–23.8)
2.90
(0.8–18.9)
8.90
(1.27–47.4)
Kruskall-Wallis analysis of variance (P value) P < 0.0001 P < 0.0001 P < 0.0001 P < 0.0001 P = NS P = NS
  1. Cathepsin B, cathepsin L, urokinase-type plasminogen activator, plasminogen activator inhibitor type-1, CEA and CA 19-9 levels in patients with colorectal cancer (n = 56), ulcerative colitis (n = 25), colorectal adenoma (n = 26) and controls (n = 35) expressed in ng/ml (median values and range)
  2. Statistics:
  3. * Colorectal cancer: P < 0.001 vs Controls
  4. § Colorectal cancer: P < 0.05 vs Ulcerative colitis and Colorectal adenoma
  5. # Colorectal adenoma: P < 0.001 vs Controls
  6. Abbreviations: CATB: cathepsin B; CATL: cathepsin L; uPA: urokinase-type plasminogen activator, PAI-1: plasminogen activator inhibitor type-1; CEA: carcinoembryonic antigen; CA 19-9: carbohydrate antigen 19-9; NS: not significant